Jeffrey Busby - Axim Biotechnologies Sr Devel
| AXIM Stock | USD 0 0 33.33% |
Insider
Jeffrey Busby is Sr Devel of Axim Biotechnologies
| Phone | 858 923 4422 |
| Web | https://www.aximbiotech.com |
Axim Biotechnologies Management Efficiency
The company has return on total asset (ROA) of (0.3465) % which means that it has lost $0.3465 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (100.1909) %, meaning that it created substantial loss on money invested by shareholders. Axim Biotechnologies' management efficiency ratios could be used to measure how well Axim Biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 3 records | INSIDER Age | ||
| Robert Madden | Grey Cloak Tech | 51 | |
| Kevin Pitts | Grey Cloak Tech | 63 | |
| Scott Landers | Grey Cloak Tech | N/A | |
Management Performance
| Return On Equity | -100.19 | |||
| Return On Asset | -0.35 |
Axim Biotechnologies Leadership Team
Elected by the shareholders, the Axim Biotechnologies' board of directors comprises two types of representatives: Axim Biotechnologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Axim. The board's role is to monitor Axim Biotechnologies' management team and ensure that shareholders' interests are well served. Axim Biotechnologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Axim Biotechnologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph MD, Chief Board | ||
| Catalina JD, I Biotech | ||
| Dr MBA, I Biotech | ||
| John II, CEO Pres | ||
| Robert Malasek, CFO Sec | ||
| Jeffrey Busby, Sr Devel | ||
| Alim SeitNebi, I Biotech |
Axim Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Axim Biotechnologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -100.19 | |||
| Return On Asset | -0.35 | |||
| Operating Margin | (847.86) % | |||
| Current Valuation | 13.6 M | |||
| Shares Outstanding | 186.44 M | |||
| Shares Owned By Insiders | 40.97 % | |||
| Price To Earning | (53.71) X | |||
| Price To Book | 2.86 X | |||
| Price To Sales | 943.93 X | |||
| Revenue | 60.46 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Axim Pink Sheet
Axim Biotechnologies financial ratios help investors to determine whether Axim Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Axim with respect to the benefits of owning Axim Biotechnologies security.